Dai Ichi Life Insurance Company Ltd decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,417 shares of the medical research company’s stock after selling 6,000 shares during the period. Dai Ichi Life Insurance Company Ltd’s holdings in Thermo Fisher Scientific were worth $10,106,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2,692.1% in the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after acquiring an additional 22,165,530 shares during the last quarter. Capital Research Global Investors lifted its holdings in shares of Thermo Fisher Scientific by 29.8% in the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after acquiring an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Thermo Fisher Scientific by 2,058.1% in the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after acquiring an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP lifted its holdings in shares of Thermo Fisher Scientific by 112.4% in the 2nd quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after acquiring an additional 1,286,259 shares during the last quarter. Finally, Harbour Capital Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 18,197.5% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after acquiring an additional 1,194,487 shares during the last quarter. Hedge funds and other institutional investors own 86.16% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (NYSE TMO) traded up $1.98 during midday trading on Thursday, reaching $191.47. 1,447,300 shares of the company’s stock traded hands, compared to its average volume of 1,562,821. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $76,380.00, a P/E ratio of 20.82, a P/E/G ratio of 1.74 and a beta of 1.06. Thermo Fisher Scientific Inc. has a twelve month low of $139.88 and a twelve month high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.03 earnings per share. research analysts predict that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is currently 10.19%.
A number of brokerages recently commented on TMO. Deutsche Bank set a $226.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Leerink Swann increased their price target on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. Finally, Cowen reaffirmed an “outperform” rating and issued a $220.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $205.21.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.49% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/14/thermo-fisher-scientific-inc-tmo-shares-sold-by-dai-ichi-life-insurance-company-ltd.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.